Pre-operative Hypofractionated Proton Therapy
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study ID
- NCT05917301
- Status
- Recruiting
Conditions
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- hypofractionation — RADIATIONThis study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
Study Details
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes / quality of life after the procedures. Patients will be asked to complete questionnaires about the treatment and quality of life from the time of enrollment until about two years after surgery. Otherwise, the participants will have standard of care follow ups with the treatment team.
Key Dates
- Start date
- Apr 18, 2024
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2032
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Pre-operative hypofractionated proton therapyPatients will have 5 fractions of proton therapy prior to surgical resection of their sarcoma.
Primary Outcome Measure
Rate of major wound complications [ Time Frame: 90 days after surgery ]
Central Contacts
- Curtiland Deville, MD202-537-4788
- Ryan Manuel
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 |
Find similar trials in Washington D.C., DC
Related Studies
- LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic OncologyPHASE4 · Enrolling By Invitation · Massachusetts General Hospital · Los Angeles, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationPHASE2 · Recruiting · Medical College of Wisconsin · Jacksonville, Florida
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee